2. Spironolactone: the workhorse anti-androgen

2.1 Mechanism

Spironolactone is a potassium-sparing diuretic and aldosterone antagonist with additional anti-androgen effects. Aldosterone is a natural hormone that primarily helps regulate blood pressure and sodium and potassium levels.

In FPL, spironolactone blocks androgen receptors in target tissues, including hair follicles, reduces androgen production in the ovaries and adrenal glands, and increases sex hormone-binding globulin in some women, lowering free testosterone levels.

The net effect is a reduction in androgen signalling at the follicle.

2.2 Evidence for hair

Spironolactone has been used in women with FPHL for decades. The bulk of the evidence comes from retrospective series and uncontrolled cohorts, smaller prospective observational studies, and, more recently, a systematic review of its use in FPHL and other forms of alopecia.

Across these studies:

• Doses typically range from 50–200 mg/day, often starting at a lower dose and titrating upward.
• A majority of women report stabilisation of hair loss and some degree of thickening or reduced shedding over 6–12 months.
• Reported “response” rates (stabilisation plus improvement) often fall wthin the 60–80% range, depending on the definition and cohort.
• One Australian prospective study of 100 women treated with low-dose oral minoxidil (0.25 mg) plus spironolactone (25 mg) daily found reduced hair shedding and severity scores at 6 and 12 months, suggesting a useful synergistic effect.

It is important to be honest: these are not placebo-controlled phase III trials. They are, however, reasonably consistent in indicating that spironolactone helps a substantial subset of women with FPHL, particularly those with signs of androgen excess.

2.3 Side-effects and monitoring

Common side-effects include:

• menstrual irregularity and spotting, particularly in the first months
• breast tenderness or enlargement
• mild fatigue, dizziness or low blood pressure in some women
• increased urination

Spironolactone can increase serum potassium, particularly at higher doses and in women with underlying kidney disease or those taking other potassium-sparing drugs. In otherwise healthy young women, dangerous hyperkalaemia is rare, but many clinicians still obtain baseline and early follow-up electrolytes, especially for doses above 100 mg/day.

Spironolactone is not suitable in pregnancy; animal data suggest a risk of feminisation of male fetuses. For that reason, it is usually combined with effective contraception if used in women of childbearing potential.

3. Cyproterone acetate and combined oral contraceptives

3.1 Cyproterone acetate (CPA)

Cyproterone acetate is a synthetic progestin with strong androgen receptor antagonism. It suppresses gonadotropins (sexual hormones) and reduces ovarian androgen production.

It is used in two broad ways:

• as a high-dose cyclic anti-androgen (for example, 50–100 mg on certain days of the cycle) often with an oestrogen,
• in low doses as the progestin component of certain combined oral contraceptives (COCs).

Evidence in FPHL includes:

• a controlled randomised trial by Vexiau et al. comparing 2% topical minoxidil with two regimens of CPA plus ethinyl oestradiol over 12 months in women with FPHL. Overall, minoxidil produced better improvement in hair density, but in the sub-group of women with clear hyperandrogenism, the CPA/oestrogen regimen performed as well as or better than minoxidil.
• observational studies and series summarised in reviews, which suggest that CPA can stabilise or modestly improve FPHL, particularly in women with hirsutism and elevated androgens.

CPA is licensed in some regions for hirsutism and severe acne with androgen excess; its use in FPHL is off-label but supported in guidelines as an option where hyperandrogenism is present.

3.2 Safety concerns with CPA

At higher cumulative doses, CPA has been linked to weight gain, mood changes, reduced libido, an increased risk of liver dysfunction, and, crucially, an increased risk of certain types of meningioma (tumours of the nervous system sheath) with long-term high-dose exposure.

Modern practice generally uses lower doses for limited durations where possible, monitors liver function and neurological symptoms, and avoids high cumulative doses in women who have other risk factors for meningioma.

CPA is also teratogenic and must be paired with contraception if used in women who could become pregnant.

3.3 Combined oral contraceptives (COCs) with anti-androgenic progestins

Some combined oral contraceptives (COCs), particularly those containing ethinyl estradiol plus drospirenone (a spironolactone analogue) or low-dose ethinyl estradiol plus cyproterone acetate (CPA), have antiandrogenic properties.

Trials in women with hirsutism demonstrate reductions in hirsutism scores, lower free androgen levels with corresponding increases in sex hormone binding globulin (SHBG), and improvements in acne.

For female pattern hair loss (FPHL), the evidence is less direct. However, these preparations are often used to regulate menstrual cycles, reduce hyperandrogenic features, and provide contraceptive cover when other antiandrogens are prescribed.

Qualitative and small quantitative reports suggest that COCs with drospirenone or CPA may help stabilise hair loss in some women, particularly when hyperandrogenism is present, but data specific to FPHL are limited.

Risks of COCs include:

• venous thromboembolism (blood clots),
• hypertension and migraines in susceptible women,
• breast tenderness and mood changes.

These need consideration alongside the potential hair benefits.

4. Flutamide: potent but problematic

Flutamide is a non-steroidal androgen receptor antagonist. It has strong anti-androgenic action and has been studied in hyperandrogenic women with alopecia.

4.1 Efficacy

The most cited study by Carmina et al. compared:

• flutamide 250 mg/day,
• CPA plus ethinyl oestradiol,
• and finasteride 5 mg/day,

in women with hyperandrogenic alopecia over one year. They found:

• flutamide reduced Ludwig scores by about 21%, indicating modest but meaningful improvement in FPHL,
• CPA and finasteride did not significantly change hair scores over the same period.

A later prospective cohort by Paradisi et al. followed hyperandrogenic women with alopecia on flutamide for up to four years. Hair scores continued to improve for around two years and then plateaued, suggesting that more prolonged therapy may deepen the response.

In treatment-resistant individual cases, women whose FPHL did not respond to spironolactone and minoxidil have shown impressive regrowth on flutamide.

4.2 Safety and why its use is limited

Flutamide’s problem is the liver.

• In the Paradisi cohort, around 4% of women stopped flutamide due to drug-related liver enzyme elevations; other series describe similar figures, and rare but serious cases of liver failure are reported in the oncology literature.
• Routine liver function monitoring is required, particularly in the first months and with dose changes.

Because of this hepatotoxicity risk, most dermatology and endocrine guidelines now recommend avoiding flutamide for FPHL unless there is a compelling reason and careful specialist oversight. Its role is largely limited to difficult hyperandrogenic cases in experienced hands.

5. Bicalutamide: a newer anti-androgen under evaluation

Bicalutamide is another non-steroidal androgen receptor antagonist, widely used in prostate cancer at high doses. At lower doses, it has been explored off-label for FPHL.

5.1 Emerging evidence

Recent retrospective and prospective work suggests:

• oral bicalutamide at doses such as 25–50 mg/day can reduce hair shedding and subjectively improve hair in women with FPHL, particularly when PCOS or other hyperandrogenic conditions co-exist.
• a large retrospective safety review of over 300 women with FPHL on bicalutamide found:
  • liver enzyme elevations in a minority, usually mild and reversible,
  • good overall tolerability,
  • discontinuation due to side-effects in a small percentage.

One 2025 cohort study reported that adding bicalutamide to ongoing regimens reduced shedding and facial hirsutism, although changes in absolute density were less striking over the follow-up period.

Injectable “mesotherapy” protocols using low-dose bicalutamide are being explored experimentally, aiming to deliver local anti-androgen effects with minimal systemic exposure. These remain research-level interventions rather than established treatments.

5.2 Safety profile

Bicalutamide appears to be less hepatotoxic than flutamide, but it is still metabolised in the liver and requires monitoring of liver function. It is teratogenic in animal models, so effective contraception is essential in women of childbearing potential. In addition, long-term safety data in women are limited.

At present, bicalutamide is best thought of as a promising option in specialist hyperandrogenic cases where standard anti-androgens are not tolerated or inadequate.

6. 5α-reductase inhibitors as “anti-androgens” in women

Finasteride and dutasteride are often grouped under anti-androgen therapy because they reduce DHT. They have been covered in detail elsewhere, so a brief summary in the female context:

• Finasteride 1 mg/day does not appear effective in postmenopausal women with FPHL (no difference from placebo at 12 months).
• Several small studies using higher doses of finasteride (2.5–5 mg) and low-dose dutasteride in postmenopausal women report stabilisation or improvement in some, particularly those with hyperandrogenic features.
• Guidelines generally suggest adding 5-ARIs or other anti-androgens only in severe FPHL or in women with androgen excess, and always on a case-by-case basis.

In premenopausal women, teratogenic risk to a male fetus is the major concern, so 5-ARIs are avoided unless contraception is well established and the benefit is deemed to outweigh risks.

Topical finasteride, often combined with minoxidil, is being explored to reduce scalp DHT with lower systemic exposure. Short-term data in women are encouraging, but long-term safety, particularly around pregnancy, is still uncertain.

7. What the guidelines and expert reviews recommend

High-quality reviews and consensus guidelines converge on a few principles:

• Minoxidil (topical or low-dose oral) is the first-line treatment for FPHL in almost all women.
• Anti-androgen therapy is particularly useful when:
  • there is clear evidence of hyperandrogenism (clinical or biochemical),
  • hair loss is severe or early-onset,
  • there is scalp hair loss plus hirsutism or acne.

Within anti-androgens:

• Spironolactone is generally considered the first choice in many settings due to its long experience and relatively good safety profile.
• Cyproterone acetate, either alone or within a COC, has a role in certain regions and in women with strong hyperandrogenic profiles, but cumulative dose and meningioma risk must be considered.
• Flutamide is effective but is largely reserved for rare, refractory cases due to hepatotoxicity.
• Bicalutamide is emerging as a potentially safer AR antagonist than flutamide, but it is still considered experimental.
• 5-ARIs are adjuncts when minoxidil and classical anti-androgens are insufficient, particularly in postmenopausal women with androgen excess.

All guidelines stress the need to exclude other causes of diffuse shedding (such as iron deficiency and thyroid disease), the importance of contraception and pregnancy planning in any hormonal therapy, and the reality that not all FPHL is androgen-dependent. As a result, some women will not respond to anti-androgen therapy even when it is hormonally safe.

8. Practical approach: Who might benefit from anti-androgens?

Women most likely to benefit include:

• those with FPHL plus clinical signs of androgen excess (hirsutism, persistent acne, irregular cycles),
• those with FPHL and confirmed hyperandrogenism on blood tests,
• young women with early-onset, rapidly progressive FPHL with a PCOS-like picture,
• women whose FPHL has not stabilised on minoxidil alone and where other causes of shedding have been excluded.

Women less likely to benefit, and in whom anti androgens may not be justified, include:

• those with mild, late-onset FPHL, stable with minoxidil, and no hyperandrogenic features,
• those with non androgenic forms of alopecia (telogen effluvium, scarring alopecias, alopecia areata), where targeting androgens will not address the primary pathology,
• women unable or unwilling to use reliable contraception where teratogenic drugs are involved.

Treatment decisions should always be individual, and revisited if response is absent after a fair trial.

9. Safety, monitoring and shared decision-making

Hormonal treatments require a bit more housekeeping than topical minoxidil.

Before starting an anti-androgen, it is sensible to:

• take a detailed history (menstrual, thrombotic, liver, renal, cardiovascular),
• review medications and psychiatric history,
• check baseline blood tests where relevant: electrolytes, liver function, androgens, SHBG, and sometimes prolactin and fasting glucose/lipids.

During treatment:

• monitor electrolytes with higher-dose spironolactone or in those with comorbidities,
• check liver enzymes periodically with CPA, flutamide or bicalutamide, especially in the first year,
• check for menstrual changes, breast changes, mood shifts, and signs of potential blood clots on combined contraceptive pills.

Contraception is non-negotiable in women of childbearing potential on spironolactone, CPA, flutamide, bicalutamide or 5-ARIs. This requires a clear, honest discussion, including what to do if a future pregnancy is desired.

Ultimately, anti-androgen therapy for hair loss is not a trivial choice. For the right woman, it can tip the balance from relentless progression to stability or gradual improvement. For the wrong woman, it adds risk without proportional benefit.